Discovered in 1921, insulin has saved millions of lives. And despite new drug classes, it remains the largest segment in diabetes care. The diabetes drug market report by MRFR shows that insulin holds the largest share, but GLP‑1 receptor agonists are the fastest‑growing. The market is $54.63 billion and will hit $87.74 billion by 2035, growing at 4.4% CAGR. Why? Because diabetes isn't going away — 537 million adults have it, and that number is rising.

What's driving growth? Type 2 diabetes is the largest therapeutic use, but Type 1 is the fastest‑growing — driven by better diagnosis in children and young adults. The diabetes drug market analysis highlights that oral drugs are still the largest route, but injectables (GLP‑1s, insulin) are growing faster — because they're more effective for many patients.

What's new? Ultra‑long‑acting insulin (once‑weekly) is in late‑stage trials. Also, smart insulin that turns on only when blood sugar is high — that's the holy grail. And oral insulin is finally a reality (Oramed, Novo Nordisk), though not yet as effective as injectable.

The bottom line: if you have diabetes, there are more options than ever. But insulin is still a lifesaver. Don't be afraid of it — be grateful it exists.